New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
July 11, 2023 - Fresenius Kabi launched an authorized brand alternative of Sanofi/Genzyme’s Mozobil (plerixafor) subcutaneous solution.
Download PDF
Return to publications
